article thumbnail

How Brevel Is Pioneering Alternative Protein from Microalgae

XTalks

Brevel , an Israeli startup specializing in the conversion of microalgae into alternative proteins, recently secured $18.5 The Tel Aviv-based startup will use the new funding to deliver an alternative protein source that is neutral in taste, highly functional, remarkably sustainable and accessible to the broader food industry.

Protein 97
article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. By reducing the movement of these muscles, wrinkles become less pronounced over time.

Botox 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

From Gene to Protein: The Journey of Protein Expression Technology

Roots Analysis

Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.

Protein 40
article thumbnail

The Active Ingredient Stands Alone

FDA Law Blog

Koblitz — One of the most important questions FDA has to answer is whether a given product is appropriately characterized as a drug, biologic, device, food, cosmetic, or something entirely different. FDA further defined the term “protein” so that it includes any peptide product that has an amino acid sequence greater than 40 amino acids.

Protein 95
article thumbnail

New Matchmaking Service Helps Food Producers Find Buyers for Unwanted Food

XTalks

Cosmetics and pharmaceutical companies can also participate in the circular economy by reducing waste and allowing other firms to create by-products. The company recently developed a plant-based, nutrition-packed protein called CanolaPROTM that was made from a by-product of crushed and oil-extracted rapeseed.

article thumbnail

Nedisertib by Merck for Neuroendocrine Tumors: Likelihood of Approval

Pharmaceutical Technology

The drug candidate targets DNA-dependent protein kinase (DNA-PK). It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials.

article thumbnail

Nedisertib by Merck for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval

Pharmaceutical Technology

The drug candidate targets DNA-dependent protein kinase (DNA-PK). It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials.